New Dual-Targeting antibody enters human trials for Hard-to-Treat cancers

NCT ID NCT07582822

Not yet recruiting Disease control Sponsor: Biotech Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The main goals are to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JH021 (a bispecific antibody targeting EGFR and cMET proteins)
What this could lead to: If successful, this could lead to a new treatment option for advanced solid tumors, especially for lung cancer patients who have stopped responding to current therapies.
What could go wrong: This is an early Phase 1 trial with only 60 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Show contact details

Locations

Henan Cancer Hospital

Zhengzhou, Henan, China
Hunan Cancer Hospital

Changsha, Hunan, China
Nanjing Tianyinshan Hospital

Nanjing, Jiangsu, China

Contact Email: •••••@•••••
Shanghai East Hospital

Shanghai, China
Shanghai Pulmonary Hospital Affiliated to Tongji University

Shanghai, Shanghai Municipality, China
Shanxi Cancer Hospital

Taiyuan, Shanxi, China
The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China
The First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, China
West China Hospital, Sichuan University

Chengdu, Sichuan, China
Yibin Second People's Hospital

Yibin, Sichuan, China
Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.